IMAX CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IMAX CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $410.21M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $352.21M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $374.84M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $300.81M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $254.88M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $55.99M | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | $37.26M | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | $8.86M | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | $34.90M | Mar 4, 2021 |
| FY2020 | Dec 31, 2019 | $124.28M | Mar 4, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $410.21M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $352.21M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $374.84M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $300.81M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $254.88M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $137.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $395.66M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $374.40M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $380.77M | Feb 19, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.19M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $190.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $214.34M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $156.36M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $134.41M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $20.31M | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | $3.83M | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | ($7.69M) | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | $5.09M | Mar 4, 2021 |
| FY2020 | Dec 31, 2019 | $62.36M | Mar 4, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.88M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $26.06M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $25.34M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($22.80M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($22.33M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($21.25M) | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | ($47.21M) | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | ($25.97M) | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | ($49.35M) | Mar 4, 2021 |
| FY2020 | Dec 31, 2019 | $18.17M | Mar 4, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.23M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $43.86M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $50.40M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($4.83M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $10.98M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($121.82M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $77.28M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $45.18M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $31.44M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $58.60M | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.82M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $10.11M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $5.30M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $6.94M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $5.62M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $5.20M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $13.73M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $20.86M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $16.32M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.46M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $132.70M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $144.41M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $138.04M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $117.32M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $108.49M | Feb 22, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.07M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $70.84M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $58.62M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $17.32M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $6.07M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($23.01M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $90.38M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $109.97M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $85.37M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $77.87M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.43M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $6.49M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $8.42M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $3.59M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $697.0K | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $7.42M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $13.37M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $24.14M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $15.28M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $894.03M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $830.40M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $814.67M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $821.15M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $883.25M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $997.75M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $889.07M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $873.60M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $866.61M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $857.33M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $466.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $452.18M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $469.08M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $491.39M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $452.88M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $532.98M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $245.97M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $274.24M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $263.00M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $230.78M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $337.89M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $299.47M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $273.14M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $263.36M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $356.08M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $394.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $547.69M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $512.16M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $527.75M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $562.01M | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.82M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $52.82M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $52.82M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $52.82M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $39.03M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $39.03M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $39.03M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $39.03M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $39.03M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $39.03M | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($239.97M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($274.68M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($292.85M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($293.12M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($234.98M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($202.85M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($40.25M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($85.39M) | Feb 19, 2020 |
| FY2018 | Jan 1, 2018 | ($60.38M) | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | ($87.59M) | Feb 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $100.59M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $76.20M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $97.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $189.71M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $317.38M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $109.48M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $141.59M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $158.73M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $204.76M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.47M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $305.68M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $18.23M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $37.75M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $25.36M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $27.32M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $29.28M | Feb 23, 2017 |
| FY2012 | Dec 31, 2012 | $11.00M | Feb 21, 2013 |
| FY2011 | Dec 31, 2011 | $55.08M | Feb 24, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 22, 2023 |
| FY2018 | Dec 31, 2018 | 0 | Feb 26, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 26, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 26, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Feb 26, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 22, 2023 |
| FY2018 | Dec 31, 2018 | 0 | Feb 26, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 26, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 26, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Feb 26, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 53.92M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 52.95M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 53.26M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 54.15M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 58.65M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 58.92M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 61.18M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 61.43M | Feb 19, 2020 |
| FY2018 | Jan 1, 2018 | 64,696 | Feb 26, 2019 |
| FY2019 | Dec 31, 2017 | 64.70M | Feb 19, 2020 |